Philip J Rosenfeld, MD, Ph.D., is a world-renown expert on age-related macular degeneration (AMD) and optical coherence tomography (OCT). He has played a pivotal role in the development of anti-VEGF therapies for neovascular and exudative eye diseases. He revolutionized the treatment of these diseases by pioneering the use of intravitreal Avastin (bevacizumab) therapy, which has prevented blindness worldwide while saving billions of dollars in healthcare expenses. He also introduced the concept of OCT-guided treatment with anti-VEGF therapy.